Tildrakizumab (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tildrakizumab" in Italian language version.

refsWebsite

Global rank Italian rank

799^th place

22^nd place

2^nd place

7^th place

4^th place

9^th place

3,257^th place

5,565^th place

low place

low place

1marketscreener.com

7,438^th place

3,725^th place

ama-assn.org

(EN) Statement on a Nonproprietary Name Adopted by the USAN Council—Tildrakizumab (PDF), su American Medical Association. URL consultato il 30 marzo 2023.

doi.org

dx.doi.org

(EN) Dolgin E, New anti-IL-23 drugs raise hopes for psoriasis plaque clearance, in Nature Biotechnology, vol. 34, n. 12, dicembre 2016, pp. 1218–1219, DOI:10.1038/nbt1216-1218, PMID 27926724.
(EN) Galluzzo M, D'adamio S, Bianchi L, Talamonti M, Tildrakizumab for treating psoriasis, in Expert Opinion on Biological Therapy, vol. 17, n. 5, maggio 2017, pp. 645–657, DOI:10.1080/14712598.2017.1304537, PMID 28271735.

marketscreener.com

m.marketscreener.com

(EN) Almirall: The European Commission approves Almirall's ILUMETRI® (tildrakizumab) for moderate-to-severe chronic plaque psoriasis, su Almirall, S.A.. URL consultato il 30 marzo 2023.

nih.gov

ncbi.nlm.nih.gov

(EN) Dolgin E, New anti-IL-23 drugs raise hopes for psoriasis plaque clearance, in Nature Biotechnology, vol. 34, n. 12, dicembre 2016, pp. 1218–1219, DOI:10.1038/nbt1216-1218, PMID 27926724.
(EN) Galluzzo M, D'adamio S, Bianchi L, Talamonti M, Tildrakizumab for treating psoriasis, in Expert Opinion on Biological Therapy, vol. 17, n. 5, maggio 2017, pp. 645–657, DOI:10.1080/14712598.2017.1304537, PMID 28271735.

oadoi.org

(EN) Dolgin E, New anti-IL-23 drugs raise hopes for psoriasis plaque clearance, in Nature Biotechnology, vol. 34, n. 12, dicembre 2016, pp. 1218–1219, DOI:10.1038/nbt1216-1218, PMID 27926724.
(EN) Galluzzo M, D'adamio S, Bianchi L, Talamonti M, Tildrakizumab for treating psoriasis, in Expert Opinion on Biological Therapy, vol. 17, n. 5, maggio 2017, pp. 645–657, DOI:10.1080/14712598.2017.1304537, PMID 28271735.

psoriasis.org

(EN) FDA approves Ilumya for plaque psoriasis, su National Psoriasis Foundation, 22 marzo 2018. URL consultato il 30 marzo 2023.